Your most informed patients no longer ask you to “fix a wrinkle.” They ask what a treatment does at the cellular level. That shift rewards practitioners who can explain the biology behind their results—and few stories are more compelling than SIRT1, the protein at the heart of modern longevity science.
This is a science-education piece for UK aesthetic practitioners. By the end, you’ll be able to explain what SIRT1 does, why it depends on NAD+, why injectable delivery beats creams and capsules, and how to turn that knowledge into a commercial advantage.
Here’s what you’ll take away:
- What SIRT1 is and why it’s called the “longevity gene”
- Why SIRT1 can’t work without NAD+—and why that matters for skin
- How NAD+ decline drives the tired look patients complain about
- Why injectable NAD+ reaches the dermis where topicals and oral supplements fall short
- How LongevHA supports SIRT1 through two routes at once
- The business case for building your menu around this science
What SIRT1 Actually Does Inside a Cell
SIRT1 (Sirtuin 1) is an enzyme your cells rely on to stay efficient and resilient. Think of it less as a single tool and more as a supervisor coordinating several of the jobs that keep a cell functioning well.
It earned the “longevity gene” label because of the range of processes it influences:
- DNA repair — helps correct the everyday damage that accumulates in a cell’s genetic code
- Cellular renewal — supports healthy turnover so cells regenerate on schedule
- Inflammation control — dampens the chronic, low-grade inflammation that wears skin down over time
- Energy metabolism — helps cells produce and manage the fuel they need to work
When SIRT1 is active, skin cells repair, renew, and produce collagen the way they should. When its activity drops, the visible signs follow: dullness, slack texture, and that flat, fatigued appearance no cream seems to reach.
The Missing Ingredient: Why SIRT1 Needs NAD+
Here’s the part worth committing to memory, because it’s the crux of the whole conversation. SIRT1 is not self-starting. It requires a coenzyme called NAD+ (nicotinamide adenine dinucleotide) to switch on and do its work.
No NAD+, no SIRT1 activity. You can have plenty of the enzyme present, but without adequate NAD+ to fuel it, it stays dormant. The two are inseparable—NAD+ is the key that turns the engine over.
That dependency reframes how you think about skin ageing. It isn’t only that cells “get old.” It’s that they run short of the specific molecule needed to keep their repair machinery online.
Why NAD+ Runs Low—and Skin Pays the Price
NAD+ isn’t fixed. Levels fall steadily with age, and the decline is significant. By the time a patient reaches their 40s, their skin cells hold far less NAD+ than they did in their 20s.
Less NAD+ means quieter SIRT1. And quieter SIRT1 means the whole system slows:
- DNA damage goes uncorrected for longer
- Cell turnover becomes sluggish
- Inflammation lingers unchecked
- Energy production dips
The clinical picture that emerges is what practitioners now call cellular fatigue—skin that looks tired and lacklustre because the cells beneath it have run low on the fuel they need to perform. Recognising this gives you a far more precise way to describe the problem to patients than “ageing.”
Why Injectable NAD+ Outperforms Topicals and Oral Supplements
If NAD+ is the answer, the obvious question is: why not simply apply it or swallow it? Delivery is where most products fail, and it’s the strongest technical point in your favour.
The topical ceiling
NAD+ is a large molecule. It struggles to cross the skin barrier intact, so most of what’s applied topically never reaches the living cells in the dermis. The label may impress; the biology rarely delivers.
The oral dilution problem
Oral NAD+ precursors raise levels across the entire body. That’s fine for general wellness, but very little of that systemic increase is directed specifically to the skin. You’re spreading a limited resource across every organ at once.
The injectable advantage
Injectable delivery sidesteps both problems. It places NAD+ directly into the dermis—precisely where the cells that repair, renew, and build collagen are working. The effect is targeted, localised, and consistent from one session to the next. For practitioners, that’s the difference between hoping an ingredient works and knowing it’s reaching its destination.
How LongevHA Supports SIRT1 From Two Directions
This is where LongevHA gives you a genuinely differentiated, science-led offering. Rather than relying on a single trigger, its “Big 5” formula activates the SIRT1 pathway through two complementary mechanisms.
NAD+ supplies the fuel. Delivered straight into the dermis, it provides the coenzyme SIRT1 needs to switch on and stay active.
Resveratrol works the second angle. It’s a well-documented sirtuin activator in its own right, helping switch on SIRT1 independently of NAD+—while also delivering antioxidant protection against the oxidative stress that damages DNA in the first place.
Supporting one pathway through two routes is smarter chemistry than stacking a single ingredient. It’s the science Dr Adams Aesthetics describes as the “time-reverse effect”: reawakening the cellular processes that keep skin behaving younger.
The rest of the Big 5 completes the system:
- Dual-weight Hyaluronic Acid (23mg/ml) — hydrates at two depths, creating the well-supported dermal environment cellular repair depends on
- Mannitol — calms post-treatment swelling and protects the HA from breaking down too quickly, extending results
- Peptides — signal the skin to build fresh collagen over time
Together, they don’t just hydrate the surface. They target the cellular fatigue behind the tired look.
The Commercial Case for Adopting This Science
Understanding SIRT1 is more than intellectual satisfaction. It’s a business tool, and here’s how it works for your clinic.
It moves you out of the price war. Standard HA boosters compete on hydration alone, which leaves patients unable to tell one treatment from another—and forces you to compete on cost. A treatment built on NAD+ and SIRT1 science gives you a story no HA-only competitor can tell. When you offer something distinct, you set the price rather than chase it.
It reframes the consult. One sentence shifts the entire conversation: “Instead of just plumping your skin, this supports the cellular pathway behind repair and renewal.” Patients who grasp they’re paying for a cellular-level upgrade invest at a premium and feel the price reflects genuine value.
It builds retention. Patients who see real improvement in skin quality—not a fortnight of plumpness—rebook and refer by name. Since keeping a patient costs far less than acquiring one, that loyalty compounds directly into profit.
It positions you ahead of the curve. The clinics that thrive over the next decade will be known for cellular health, not volume alone. Adopting NAD+ injectables now, while the category is still forming, claims that position while the advantage is greatest.
The Bottom Line
SIRT1 is the protein that keeps skin cells repairing, renewing, and controlling inflammation—but it can’t act without NAD+, and NAD+ falls sharply with age. Topicals can’t reach it and oral supplements dilute it, which is why injectable delivery into the dermis is the logical next step for aesthetics.
LongevHA supports that pathway through two complementary mechanisms—NAD+ supplying the fuel and Resveratrol activating sirtuins from a second angle—all within a Big 5 formula built around the “time-reverse effect.” Master this one story, and you hand your clinic a durable, science-led edge.
Ready to bring SIRT1 science to your treatment menu? Visit Dr Adams Aesthetics and secure your batch of LongevHA today.
